Lipid-based drug delivery systems for cancer treatment

Current Drug Targets

Volumn 12, Issue 8, 2011, Pages 1151-1165

  Arias, J L ^a   Clares, B ^a   Morales, M E ^a   Gallardo, V ^a   Ruiz, M A ^a  

^a UNIVERSITY OF GRANADA   (Spain)

Author keywords

Cancer; Enhanced permeability and retention effect; Ligand mediated targeting; Liposomes; Multi drug resistance (mdr); Niosomes; Solid lipid nanoparticles (sln); Stimuli sensitive carrier

Indexed keywords

CAMPTOTHECIN; LIPOSOME; NIOSOME; SOLID LIPID NANOPARTICLE;

ANTINEOPLASTIC ACTIVITY; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER TISSUE; CONTROLLED DRUG RELEASE; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG RETENTION; DRUG TARGETING; GENE TARGETING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MULTIDRUG RESISTANCE; NANOMEDICINE; NONHUMAN; REVIEW; ULTRASOUND;

ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; HUMANS; LIPIDS; LIPOSOMES; NANOMEDICINE; NANOPARTICLES; NEOPLASMS;

EID: 79959306155     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011795906570     Document Type: Review

References (256)

1. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 2001; 46: 149-68.
2. Reddy LH. Drug delivery to tumors: recent strategies. J Pharm Pharmacol 2005; 57: 1231-42.
3. Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008; 7: 771-82.
4. Arias JL, Galllardo V, Gómez-Lopera SA, Plaza RC, Delgado AV. Synthesis and characterization of poly(ethyl-2-cyanoacrylate) nanoparticles with a magnetic core. J Control Release 2001; 77: 309-21.
5. Vora B, Khopade AJ, Jain NK. Proniosome based transdermal delivery if levonorgestrel for effective contraception. J Control Release 1998; 54: 149-65.
6. Uchegbu IF, Double JA, Kelland LR, Turton JA, Florence AT. The activity of doxorubicin niosomes against an ovarian cancer cell line and three in vivo mouse tumour models. J Drug Target 1996; 3: 399-409.
7. Bangham AD, Standish MM, Watkins JC. Diffusion of swollen lipids. J Mol Biol 1965; 13: 238-52.
8. Szoka F Jr, Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci USA 1978; 75: 4194-8.
9. Mozafari MR, Reed CJ, Rostron C. Cytotoxicity evaluation of anionic nanoliposomes and nanolipoplexes prepared by the heating method without employing volatile solvents and detergents. Die Pharmazie 2007; 62: 205-9.
10. Kikuchi H, Yamauchi H, Hirota S. A polyol dilution method for mass production of liposome. J Liposome Res 1994; 4: 71-91.
11. Batzri S, Korn ED. Single bilayer liposomes prepared without sonication. Biochim Biophys Acta 1973; 289: 1015-9.
12. Heo JH, Kim SY, Kim HS, Yoo KP. Enzymatic preparation of a carbohydrate ester of medium-chain fatty. Biotechnol Lett 2000; 22: 995-8.
13. Cooper AJ. Synthesis and processing of polymers using supercritical carbon dioxide. J Mater Chem 2000; 10: 207-37.
14. Manosroi A, Chutopraprat R, Abe M, Manosroi J. Characteristics of niosomes prepared by supercritical carbon dioxide (scCO2) fluid. Int J Pharm 2008; 352: 248-55.
15. Muzzalupo R, Tavano L, Trombino S, Cassano R, Picci N, La Mesa C. Niosomes from alpha,omega-trioxiethilene-bis(sodium 2- dodecyloxy-propylenesulfonate): preparation and characterization. Colloids Surf B Biointerfaces 2008; 68: 200-7.
16. Paolino D, Cosco D, Muzzalupo R, Trapasso E, Picci N, Fresta M. Innovative bola-surfactant niosomes as topical delivery systems of 5-fluorouracil for the treatment of skin cancer. Int J Pharm 2008; 353: 233-42.
17. Huang Y, Chen J, Chen X, Gao J, Liang W. PEGylated synthetic surfactantvesicles (Niosomes): novel carriers for oligonucleotides. J Mater Sci Mater Med 2008; 19: 607-14.
18. Hong M, Zhu S, Jiang Y, Tang G, Pei Y. Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin. J Control Release 2009; 133: 96-102.
19. Shi B, Fang C, Pei Y. Stealth PEG-PHDCA niosomes: effects of chain lenght of PEG and particle size on niosomes surface properties, in vitro drug release, phagocytic uptake, in vivo pharmacokinetics and antitumor activity. J Pharm Sci 2006; 95: 1873-87.
20. Fu JY, Blatchford DR, Tetley L, Dufès C. Tumor regression after systemic administration of tocotrienol entrapped in tumor-targeted vesicles. J Control Release 2009; 140: 95-9.
21. Gregoriadis G. Drug entrapment in liposomes. FEBS Lett 1973; 36: 292-6.
22. Gregoriadis G, Wills EF, Swain CP, Tavill AS. Drug carrier potential of liposomes in cancer chemotherapy. Lancet 1974; 1: 1313-7.
23. Gregoriadis G. Liposomes in drug and vaccine delivery. Drug Des Deliv 2003; 2: 91-7.
24. Zanin MHA, Torriani ICL, Zollner RL, Santana MHA. Physical characterization of surface-modified liposomes by incorporation of gangliosides designed for immunotherapies. Colloids Surf A Physicochem Eng Asp 2004; 251: 175-82.
25. Clares B, Medina MM, Gallardo V, Ruíz MA. Multilamellar Liposomes of Triamcinolone Acetonide: Preparation, Stability and Characterization. J Liposome Res 2009; 19: 197-206.
26. Papahadjopoulos D, Gabizon A. Targeting of liposomes to tumor cells in vivo. Ann NY Acad Sci 1987; 504: 64-74.
27. Needham D, McIntosh TJ, Lasic DD. Repulsive interactions and mechanical stability of polymer-grafted lipid membranes. Biochim Biophys Acta 1992; 1108: 40-8.
28. Fang JY, Hong CT, Chiu WT, Wang YY. Effect of liposomes and niosomes on skin permeation of enoxacin. J Control Release 1999; 60: 1-10.
29. Kulkarni SB, Vargha-Butler EI. Study of liposomal drug delivery systems 2. Encapsulation efficiencies of some steroids in MLV liposomes. Colloids Surf B Biointerfaces 1995; 4: 77-85.
30. Iwamoto Y, Matsumoto Y, Ueoka R. Induction of apoptosis of human lung carcinoma cells by hybrid liposomes containing polyoxyethylenedodecyl ether. Int J Pharm 2005; 292: 231-9.
31. Nagami H, Matsumoto Y, Ueoka R. Chemotherapy with hybrid liposomes for lymphoma without drugs in vivo. Int J Pharm 2006; 315: 167-72.
32. Shimoda S, Ichihara H, Matsumoto Y, Ueoka R. Chemotherapy with hybrid liposomes for human breast tumors along with apoptosis in vivo. Int J Pharm 2009; 372: 162-8.
33. Kirby C, Clarke J, Gregoriadis G. Transfer and exchange of phospholipid loss to high density lipoproteins in the presence of serum. FEBS Lett 1980; 111: 324-9.
34. Damen J, Regts J, Scherphof G. Transfer and exchange of phospholipid between small unilamellar liposomes and rat plasma high density lipoproteins. Dependence on cholesterol content and phospholipid composition. Biochim Biophys Acta 1981; 665: 538-48.
35. Mauk MR, Gamble RC, Baldeschwieler JD. Targeting of lipid vesicles: Specificity of carbohydrate receptor analogues for leukocytes in ice. Proc Natl Acad Sci USA 1980; 77: 4430-4.
36. Opanasopit P, Sakai M, Nishikawa M, Kawakami S, Yamashita F, Hashida M. Inhibition of liver metastasis by targeting of immunomodulators using mannosylated liposome carriers. J Control Release 2002; 80: 283-94.
37. Vemuri S, Rhodes CT. Preparation and characterization of liposomes as therapeutic delivery systems: a review. Pharm Acta Helv 1995; 70: 95-111.
38. Bin D, Ying L, Xiaotian L, Youmei A, Chengqun C, Zhenzhong Z. Preparation, characterization and in vivo evaluation of 2- methoxyestradiol-loaded liposomes. Int J Pharm 2010; 384: 140-7.
39. Kreuschner K. In: Schmidt KH, Ed. Liposomes as Drug Carriers. Stuttgart, Kurzt-Deuts Biblio 1986; pp. 8-25.
40. Hamilton RL, Goerke J, Guo L. Unilamellar liposomes made with the French pressure cell: A simple preparative and semiquantitative technique. J Lipid Res 1980; 21: 981-92.
41. Baren-Holz Y, Amselem S, Lichtenberg D. A new method for preparation of phospholipid vesicles. FEBS Lett 1979; 99: 210-4.
42. Deamer DW, Bangham AD. Large volume liposomes by an ether vaporization method. Biochim Biophys Acta 1976; 443: 629-33.
43. Ohsawa T, Miura H, Harada K. A novel method for preparing liposome with a high capacity to encapsulate proteinous drugs: Freeze-drying method. Chem Pharm 1984; 32: 2442-5.
44. Olson F, Hunt CA, Szoka FC, Vail WJ, Papahadjopoulos D. Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. Biochim Biophys Acta 1984; 557: 9-23.
45. Elmi MM, Sarbolouki MN. A simple method for preparation of immuno-magnetic liposomes. Int J Pharm 2001; 215: 45-50.
46. Cortesi R. Preparation of liposomes by reverse-phase evaporation using alternative organic solvents. J Microencapsul 1999; 16: 251-6.
47. Mayhew E, Nickolopoulos GT, King JJ, Siciliano AA. A practical method for the large scale manufacture of liposome. Pharm Manufact 1985; 2: 18-21.
48. Vemuri S, Yu C, Wangsatorntanakun V, Roosdorp N. Large-scale production of liposomes by microfluidizer. Drug Dev Ind Pharm 1990; 16: 2243-56.
49. Papahadjopoulos D, Vail WJ, Jakobson K, Poste G. Colcheate lipid cylinders: Formation by fusion of unilamellar vesicles. Biochim Biophys Acta 1975; 394: 483-91.
50. Collins D, Connor J, Ting-Beall HP, Huang L. Proton and divalent cations induce synergistic but mechanistically different destabilizations of pH-sensitive liposomes composed of dioleoyl phosphatidylethanolamine and oleic acid. Chem Phys Lipids 1990; 55: 339-49.
51. Yatvin MB, Lelkes PI. Clinical prospects for liposomes. Med Phys 1982; 9: 149-75.
52. Huwyler J, Drewe J, Krähenbühl S. Tumor targeting using liposomal antineoplastic drugs. Int J Nanomed 2008; 3: 21-9.
53. Merdan T, Kopecek J, Kissel T. Prospects for cationic polymers in gen and oligonucleotide therapy against cancer. Adv Drug Deliv Rev 2002; 54: 715-22.
54. Parker RJ, Priester ER, Sieber SM. Comparison of lymphatic uptake, metabolism, excretion, and biodistribution of free and liposome entrapped [14C]cytosine beta-D-arabinofuranoside following intraperitoneal administration to rats. Drug Metab Dispos 1982; 10: 40-6.
55. Tacker JR, Anderson RU. Delivery of antitumor drug to bladder cancer by use of phase transition liposomes and hyperthermia. J Urol 1982; 127: 1211-4.
56. Park JW, Benz CC, Martin FJ. Future directions of liposome and immunoliposome-based cancer therapeutics. Semin Oncol 2004; 31: 196-205.
57. Andresen TL, Jensen SS, Jørgensen K. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res 2005; 44: 68-97.
58. Hofheinz RD, Gnad-Vogt SU, Beyer U, Hochhaus A. Liposomal encapsulated anti-cancer drugs. Anticancer Drugs 2005; 16: 691-707.
59. Rahman A, White G, More N, Schein PS. Pharmacological, toxicological, and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes. Cancer Res 1985; 45: 796-803.
60. Kojima N, Ueno N, Tacaño M, et al. Effect of adriamycin entrapped by sulfatide-containing liposomes on ovarian tumorbearing nude mice. Biotechnol Appl Biochem 1986; 8: 471-8.
61. Cervato G, Viani P, Galatulas I, Bossa R, Cestaro B. In vitro and in vivo studies with anionic sulfatide-liposomes containing adriamycin. Anticancer Res 1986; 6: 1287-90.
62. Elorza B, Elorza MA, Frutos G, Chantres JR. Characterization of 5- fluorouracil loaded liposomes prepared by reverse-phase evaporation or freezing-thawing extrusion methods: study of drug release. Biochim Biophys Acta 1993; 1153: 135-42.
63. Nii T, Ishii F. Encapsulation efficiency of water-soluble and insoluble drugs in liposomes prepared by the microencapsulation vesicle method. Int J Pharm 2005; 298: 198-205.
64. Sasaki H, Matsukawa Y, Hashida M, Sezaki H. Characterization of alkylcarbamoyl derivatives of 5-fluorouracil and their application to liposome. Int J Pharm 1987; 36: 147-56.
65. Sun W, Zhang N, Aiguo L, Zou W, Xu W. Preparation and evaluation of N3-O-toluyl-loaded liposomes. Int J Pharm 2008; 353: 243-50.
66. Fresta M, Villari A, Puglisi G, Cavallaro G. 5-Fluorouracil: various kinds of loaded liposomes: encapsulation efficiency, storage stability and fusogenic properties. Int J Pharm 1993; 99: 145-56.
67. Glavas-Dodov M, Fredro-Kumbaradzi E, Goracinova K, et al. The effects of lyophilization on the stability of liposomes containing 5- FU. Int J Pharm 2005; 291: 79-86.
68. Wang T, Deng Y, Geng Y, Gao Z, Zou J, Wang Z. Preparation of submicron unilamellar liposomes by freeze-drying double emulsions. Biochim Biophys Acta 2006; 1758: 222-31.
69. Watanabe M, Kawano K, Toma K, Hattori T, Maitani Y. In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin. J Control Release 2008; 127: 231-8.
70. Yamamoto K, Mizutani Y, Nakanishi H, et al. Significant antitumor activity of cationic multilamellar liposomes containing human interferon-beta gene in combination with 5-fluorouracil against human renal cell carcinoma. Int J Oncol 2008; 33: 565-71.
71. Derycke ASL, de Witte PAM. Liposomes for photodynamic therapy. Adv Drug Deliv Rev 2004; 56: 17-30.
72. Ichikawa K, Hikita T, Maeda N, et al. Antiangiogenic photodynamic therapy (PDT) by using long-circulating liposomes modified with peptide specific to angiogenic vessels. Biochim Biophys 2005; 1669: 69-74.
73. Damoiseau X, Schuitmaker HJ, Lagerberg JW, Hoebeke M. Increase of the photosensitizing efficiency of the Bacteriochlorin a by liposome-delivered incorporation. J Photochem Photobiol 2001; 60: 50-60.
74. Takeuchi H, Kojima H, Yamamoto H, Kawashima Y. Passive targeting of doxorubicin with polymer coated liposomes in tumor bearing rats. Biol Pharm 2001; 24: 795-9.
75. Moreira JN, Almeida LM, Geraldes CF, Costa ML. Evaluation of in vitro stability of large unilamellar liposomes coated with modified polysacharide (O-palmitoylpullulan). J Mater Sci Mater Med 1996; 7: 301-6.
76. Moreira JN, Almeida LM, Geraldes CF, Madeira VMC, Costa ML. Carboplatin liposomes coated with O-palmitoylpullulan: In vitro characterization. Inter J Pharm 1997; 147: 153-9.
77. Slepushkin VA, Simões S, Dazin P, et al. Sterically stabilized pHsensitive liposomes. Intracellular delivery of aqueous contents and prolonged circulation in vivo. J Biol Chem 1997; 272: 2382-8.
78. Takeuchi H, Kojima H, Toyoda T, Yamamoto H, Hino T, Kawashima Y. Prolonged circulation time of doxorubicin loaded liposomes coated with a modified polyvinyl alcohol after intravenous injection in rats. Eur J Pharm Biopharm 1999; 48: 123-9.
79. Han HD, Lee A, Hwang T, et al. Enhanced circulation time and antitumor activity of doxorubicin by comblike polymerincorporated liposomes. J Control Release 2007; 120: 161-8.
80. Chang MY, Seideman J, Sofou S. Enhanced loading efficiency and retention of 225Ac in rigid liposomes for potential targeted therapy of micrometastases. Bioconjug Chem 2008; 19: 1274-82.
81. Allen TM. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci 1994; 15: 215-20.
82. Hau P, Fabel K, Baumgart U, et al. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 2004; 100: 1199-207.
83. Lasic DD. Doxorubicin in sterically stabilized liposomes. Nature 1996; 380: 561-2.
84. Wong JY, Kuhl TL, Israelachvili JN, Mullah N, Zalipsky S. Direct measurement of a tethered ligand-receptor interaction potential. Science 1997; 275: 820-2.
85. Photos PJ, Bacakova L, Discher B, Bates FS, Discher DE. Polymer vesicles in vivo: correlations with PEG molecular weight. J Control Release 2003; 90: 323-34.
86. Safra T, Muggia F, Jeffers S, et al. Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500mg/m2. Ann Oncol 2000; 11: 1029-33.
87. Oku N, Saito S, Namba Y, Tsukada H, Dolphin D, Okada S. Application of long-circulating liposomes to cancer photodynamic therapy. Biol Pharm 1997; 20: 670-3.
88. Celia C, Calvagno MG, Paolino D, et al. Improved in-vitro antitumoral activity, intracellular uptake and apoptotic induction of gemcitabine-loaded pegylated unilamellar liposomes. J Nanosci Nanotechnol 2008; 8: 2102-13.
89. Fens MH, Hill KJ, Issa J, et al. Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma. Br J Cancer 2008; 99: 1256-64.
90. Gijsens A, Missiaen L, Merlevede W, De Witte P. Epidermal growth factor-mediated targeting of chlorin e6 selectively potentiates its photodynamic activity. Cancer Res 2000; 60: 2197-202.
91. Qualls MM, Thompson DH. Chloroaluminum phthalocyanine tetrasulfonate delivered via acid-labile diplasmenylcholine-folate liposomes: Intracellular localization and synergistic phototoxicity. Int J Cancer 2001; 93: 384-92.
92. Renno RZ, Miller JW. Photosensitizer delivery for photodynamic therapy of choroidal neovascularization. Adv Drug Deliv Rev 2001; 52: 63-78.
93. Gijsens A, Derycke A, Missiaen L, et al. Targeting of the photocytotoxic compound AlPcS4 to HeLa cells by transferrin conjugated PEGliposomes. Int J Cancer 2002; 101: 78-85.
94. Thole M, Nobmanna S, Huwyler J, Bartmann A, Fricker G. Uptake of cationzied albumin coupled liposomes by cultured porcine brain microvessel endothelial cells and intact brain capillaries. J Drug Target 2002; 10: 337-44.
95. Yonghua Z, Lili G, Roger R, Asok A, Hiremagalur J. Pteroyl-?- glutamate-cysteine synthesis and its application in folate receptormediated cancer cell targeting using folate-tethered liposomes. Anal Biochem 2004; 332: 168-77.
96. Fonseca C, Moreira JN, Ciudad CJ, Pedroso de Lima MC, Simões S. Targeting of sterically stabilised pH-sensitive liposomes to human T-leukaemia cells. Eur J Pharm Biopharm 2005; 59: 359-66.
97. Terada T, Mizobata M, Kawakami S, Yamashita F, Hashida M. Optimization of tumor-selective targeting by basic fibroblast growth factor-binding peptide grafted PEGylated liposomes. J Control Release 2007; 119: 262-70.
98. Song CK, Jung SH, Kim DD, Jeong LS, Shin BC, Seong H. Disaccharide-modified liposomes and their in vitro intracellular uptake. Int J Pharm 2009; 380: 161-9.
99. Fenart L, Casanova A, Dehouck B, et al. Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier. J Pharmacol Exp Ther 1999; 291: 1017-22.
100. Rensen PCN, Schiffelers RM, Versluis AJ, et al. Human recombinant apolipoprotein E-enriched liposomes can mimic lowdensity lipoproteins as carriers for thesite-specific delivery of antitumor agents. Mol Pharm 1997; 52: 445-55.
101. Xu L, Huang CC, Huang W. Systemic tumor-targed gene delivery by anti-transferrin receptor scFv-inmunoliposomes. Mol Cancer Ther 2002; 1: 337-44.
102. Raffaghello L. Inmunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma. Cancer Lett 2003; 297: 151-5.
103. Hamaguchi T, Matsumura Y, Nakanishi Y, et al. Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts. Cancer Sci 2004; 95: 608-13.
104. Matsumura Y, Gotoh M, Muro K, et al. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol 2004; 15: 517-25.
105. Schnyder A, Krähenbül S, Drewe J, Huwyler J. Targeting of daunomycin using biotinylated immunoliposomes: pharmacokinetics, tissue distribution and in vitro pharmacological effects. J Drug Target 2005; 13: 325-35.
106. Maruyama K, Holmberg E, Kennel SJ, Klibanov A, Torchilin VP, Huang L. Characterization of in vivo immunoliposome targeting to pulmonary endothelium. J Pharm Sci 1990; 79: 978-84.
107. Maruyama K, Takizawa T, Yuda T, Kennel SJ, Huang L, Iwatsuru M. Targetability of novel immunoliposomes modified with amphipatic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal-antibodies. Biochim Biophys Acta 1995; 1234: 74-80.
108. Maruyama K, Ishida O, Takizawa T, Moribe K. Possibility of active targeting to tumor tissues with liposomes. Adv Drug Deliv Rev 1999; 40: 89-102.
109. Sapra P, Allen TM. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res 2003; 42: 439-62.
110. Magee WE, Cromen JH, Thor DE. Marked stimulation of lymphocyte-mediated attack on tumor cells by target-directed liposomes containing immune RNA. Cancer Res 1978; 38: 1173-6.
111. Kirpotin D, Park JW, Hong K, et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 1997; 36: 66-75.
112. Park JW, Kirpotin DB, Hong K, et al. Anti-HER2 immunoliposomes: enhanced anticancer efficacy due to targeted delivery. J Control Release 2001; 74: 95-113.
113. Park JW, Hong K, Kirpotin DB, et al. Anti-HER2 immunoliposomes: enhanced efficacy due to targeted delivery. Clin Cancer Res 2002; 8: 1172-81.
114. Elbayoumi TA, Torchilin VP. Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines European. J Pharm Sci 2007; 32: 159-68.
115. Gosk S, Moos T, Gottstein C, Bendas G. VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo. Biochim Biophys Acta 2008; 1778: 854-63.
116. Suzuki S, Inoue K, Hongoh A, Hashimoto Y, Yamazoe Y. Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferrin receptor. Br J Cancer 1997; 76: 83-9.
117. Matsuo H, Wakasugi M, Takanaga H, et al. Possibility of the reversal of multidrug resistance and the avoidance of side effects by liposomes modified with MRK-16, a monoclonal antibody to Pglycoprotein. J Control Release 2001; 77: 77-86.
118. Mamot C, Drummond DC, Hong K, Kirpotin DB, Park JW. Liposome-based approaches to overcome anticancer drug resistance. Drug Resist Updat 2003; 6: 271-9.
119. Zhang Y, Zhu C, Pardridge WM. Antisense gene therapy of brain cancer with an artificial virus gene delivery system. Mol Ther 2002; 6: 67-72.
120. Zhang Y, Schlachetzki F, Pardridge WM. Global non-viral gene transfer to the primate brain following intravenous administration. Mol Ther 2003; 7: 11-8.
121. Shi N, Pardridge WM. Noninvasive gene targeting to the brain. Proc Natl Acad Sci USA 2000; 97: 7567-72.
122. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279: 377-80.
123. Schiffelers RM, Koning GA, ten Hagen TL, et al. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J Control Release 2003; 91: 115-22.
124. Dubey PK, Mishra A, Jain S, Mahor A, Vyas SP. Liposomes modified with cyclic RGD peptide for tumor targeting. J Drug Target 2004; 12: 257-66.
125. Yuan WM, Song QG, Zhang ZR, Fu Y, Liu J, He Q. LHRHa aided liposomes targeting to human ovarian tumor cells: preparation and cellular uptake. Pharmazie 2008; 63: 434-8.
126. Garg A, Tisdale AW, Haidari E, Kokkoli E. Targeting colon cancer cells using PEGylated liposomes modified with a fibronectinmimetic peptide. Int J Pharm 2009; 366: 201-10.
127. Mai J, Song S, Rui M, et al. A synthetic peptide mediated active targeting of cisplatin liposomes to Tie2 expressing cells. J Control Release 2009; 139: 174-81.
128. Hood JD, Bednarski M, Frausto R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science 2002; 296: 2404-7.
129. Gabizon A, Horowitz AT, Goren D, et al. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. Bioconjug Chem 1999; 10; 289-98.
130. Leamon CP, Cooper SR, Hardee GE. Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo. Bioconjug Chem 2003; 14: 738-47.
131. Saul JM, Annapragada A, Natarajan JV, Bellamkonda RV. Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J Control Release 2003; 92: 49-67.
132. Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev 2004; 56: 1177-92.
133. Shmeeda H, Mak L, Tzemach D, Astrahan P, Tarshish M, Gabizon A. Intracellular uptake and intracavitary targeting of folateconjugated liposomes in a mouse lymphoma model with upregulated folate receptors. Mol Cancer Ther 2006; 5: 818-24.
134. Pan XQ, Lee RJ. In vivo antitumor activity of folate receptortargeted liposomal daunorubicin in a murine leukemia model. Anticancer Res 2005; 25: 343-6.
135. Pan XQ, Zheng X, Shi GF, Wang HQ, Ratnam M, Lee RJ. Strategy for the treatment of acute myelogenous leukemia based on folate receptor-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoid acid. Blood 2002; 100: 594-602.
136. Pan XQ, Wang HQ, Lee RJ. Antitumor activity of folate receptortargeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model. Pharm Res 2003; 20: 417-22.
137. Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res 2000; 6: 1949-57.
138. Gerasimov OV, Boomer JA, Qualls MM, Thompson DH. Cytosolic drug delivery using pH- and light-sensitive liposomes. Adv Drug Deliv Rev 1999; 38: 317-38.
139. Ying X, Wen H, Lu WL, et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Release 2010; 141: 183-92.
140. Eavarone DA, Yu X, Bellamkonda RV. Targeted drug delivery to C6 glioma by transferrin-coupled liposomes. J Biomed Mater Res 2000; 51: 10-4.
141. Soni V, Kohli DV, Jain SK. Transferrin coupled liposomes as drug delivery carriers for brain targeting of 5-florouracil. J Drug Target 2005; 13: 245-50.
142. Wu J, Lu Y, Lee A, et al. Reversal of multidrug resistance by transferrin-conjugated liposomes coencapsulating doxorubicin and verapamil. J Pharm Pharm Sci 2007; 10: 350-7.
143. Pakunlu RI, Wang Y, Saad M, Khandare JJ, Starovoytov V, Minko T. In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. J Control Release 2006; 114: 153-62.
144. Willis MC, Collins BD, Zhang T, et al. Liposome-anchored vascular endothelial growth factor aptamers. Bioconjug Chem 1998; 9: 573-82.
145. Margolis LB, Namit VA. Magnetoliposomes: Another principle of cell sorting. Biochem Biophys Acta 1983; 735: 193-5.
146. Kato Y, Kiwada H. Feasability of magnetic liposomes as a targeting device for drugs. Chem Pharm 1986; 34: 4253-8.
147. Scheffold A, Milteni S. Magnetofluorescent liposomes for increased sensitivity of immunofluorescence. Immunotechnology 1995; 1: 127-37.
148. Jain S, Mishra V, Singh P, Dubey PK, Saraf DK, Vyas SP. RGDanchored magnetic liposomes for monocytes/neutrophils-mediated brain targeting. Int J Pharm 2003; 261: 43-55.
149. Dandamudi S, Campbell RB. Development and characterization of magnetic cationic liposomes for targeting tumor microvasculature. Biochim Biophys Acta 2007; 1768: 427-38.
150. Dandamudi S, Campbell RB. The drug loading, cytotoxicty and tumor vascular targeting characteristics of magnetite in magnetic drug targeting. Biomaterials 2007; 28: 4673-83.
151. Plassat V, Martina MS, Barratt G, Ménager C, Lesieur S. Sterically stabilized superparamagnetic liposomes for MR imaging and cancer therapy: Pharmacokinetics and biodistribution. Int J Pharm 2007; 344: 118-27.
152. Bergemann C, Müller-Schulte D, Oster J, Brassardm L, Lübbe AS. Magnetic iron-exchange nano- and microparticles for medical, biochemical and molecular biological applications. J Magn Magn Mater 1999; 194: 45-52.
153. Bulte JWM, de Cuyper M, Despres D, Frank JA. Preparation, relaxometry, and biokinetics of PEGylated magnetoliposomes as MR contrast agent. J Magn Magn Mater 1999; 194: 204-9.
154. de Cuyper M, Soenen SJH, Coenegrachts K, Beek LT. Surface functionalization of magnetoliposomes in view of improving iron oxide-based magnetic resonante imaging contrast agents: Anchoring of gadolinium ions to a lipophilic chelate. Anal Biochem 2007; 367: 266-73.
155. Gonzales M, Krishnan KM. Synthesis of magnetoliposomes with monodisperse iron oxide nanocrystal cores for hyperthermia. J Magn Magn Mater 2005; 293: 265-70.
156. Kuznetsov AA, Filippov VI, Alyautdin RN, Torshina NL, Kuznetsov OA. Application of magnetic liposomes for magnetically guided transport of muscle relaxants and anti-cancer photodynamic drugs. J Magn Magn Mater 2001; 225: 95-100.
157. Lang C, Schüler D. Biogenic nanoparticles: production, characterization and application of bacterial magnetosomes. J Phys Condens Matter 2006; 18: S2815-28.
158. Huang X, Bronstein LM, Retrum J, et al. Self-assembled virus-like particles with magnetic cores. Nano Lett 2007; 7: 2407-16.
159. Lang C, Schüler D, Faivre D. Synthesis of magnetite nanoparticles for bio- and nanotechnology: genetic engineering and biomimetics of bacterial magnetosomes. Macromol Biosci 2007; 7: 144-51.
160. Sabaté R, Barnadas-Rodríguez R, Callejas-Fernández J, HidalgoÁlvarez R, Estelrich J. Preparation and characterization of extruded magnetoliposomes. Int J Pharm 2008; 347: 156-62.
161. Martina MS, Fortin JP, Menager C, et al. Generation of superparamagnetic liposomes revealed as highly efficient MRI contrast agents for in vivo imaging. J Am Chem Soc 2005; 127: 10676-85.
162. Xiang L, Wei J, Jianbo S, Guili W, Feng G, Ying L. Purified and sterilized magnetosomes from Magnetospirillum gryphiswaldense MSR-1 were not toxic to mouse fibroblasts in vitro. Lett Appl Microbiol 2007; 45: 75-81.
163. Wu NZ, Da D, Rudoll TL, Needham D, Whorton AR, Dewhirst MW. Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumor tissue. Cancer Res 1993; 53: 3765-70.
164. Huang SK, Stauffer PR, Hong K, et al. Liposome and hyperthermiain mice: increased tumor uptake and therapeutic efficacy of Doxorubicin in sterically stabilized liposomes. Cancer Res 1994; 54: 218-9.
165. Needham D, Dewhirst MW. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev 2001; 53: 285-305.
166. Kong G, Anyarambhatla G, Petros WP, et al. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res 2000; 60: 6950-7.
167. Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res 2000; 60: 1197-201.
168. Gaber MH, Hong K, Huang SK, Papahadjopoulos D. Thermosensitive sterically stabilized liposomes: formulation and in vitro studies on mechanism of doxorubicin release by bovine serum and human plasma. Pharm Res 1995; 12: 1407-16.
169. Gaber MH, Wu NZ, Hong K, Huang SK, Dewhirst MW, Papahadjopoulos D. Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. Int J Radiat Oncol Biol Phys 1996; 36: 1177-87.
170. Meyer O, Papahadjopoulos D, Leroux JC. Copolymers of Nisopropylacrylamide can trigger pH sensitivity to stable liposomes. FEBS Lett 1998; 421: 61-4.
171. Kono K, Nakai R, Morimoto K, Takagishi T. Thermosensitive polymer modified liposomes that release contents around physiological temperature. Biochim Biophys Acta 1999; 1416: 239-50.
172. Kono K, Henmi A, Takagishi T. Temperature-controlled interaction of thermosensitive polymer-modified cationic liposomes with negatively charged phospholipid membranes. Biochim Biophys Acta 1999; 1421: 183-97.
173. Kono K. Thermosensitive polymer-modified liposomes. Adv Drug Deliv Rev 2001; 53: 307-19.
174. Shen Z, Wei W, Zhao Y, et al. Thermosensitive polymerconjugated albumin nanospheres as thermal targeting anti-cancer drug carrier. Eur J Pharm Sci 2008; 35: 271-82.
175. Torchilin VP, Zhou F, Huang L. pH-sensitive liposomes. J Liposome Res 1993; 3: 201-55.
176. Kono K, Zenitani K, Takagishi T. Novel pH-sensitive liposomes: Liposomes bearing a poly(ethylene glycol) derivative with carboxyl groups. Biochim Biophys Acta 1994; 1193: 1-9.
177. Mizoue T, Horibe T, Maruyama K, et al. Targetability and intracellular delivery of anti-BCG antibody-modified, pHsensitive fusogenic immunoliposomes to tumor cells. Int J Pharm 2002; 237: 129-37.
178. Provoda CJ, Stier EM, Lee KD. Tumor cell killing enabled by listeriolysin O-liposome-mediated delivery of the protein toxin gelonin. J Biol Chem 2003; 278: 35102-8.
179. Nir S, Nicol F, Szoka FC. Surface aggregation and membrane penetration by peptides: relation to pore formation and fusion. Mol Membr Biol 1999; 16: 95-101.
180. Leroux J, Roux E, Le Garrec D, Hong K, Drummond DC. NIsopropylacrylamide copolymers for the preparation of pH-sensitive liposomes and polymeric micelles. J Control Release 2001; 72: 71-84.
181. Mastrobattista E, Koning GA, Van Bloois L, Filipe AC, Jiskoot W, Storm G. Functional characterization of an endosome- disruptive peptide and its application in cytosolic delivery of immunoliposome- entrapped proteins J Biol Chem 2002; 277: 27135-43.
182. Roux E, Francis M, Winnik FM, Leroux JC. Polymer based pHsensitive carriers as a means to improve the cytoplasmic delivery of drugs. Int J Pharm 2002; 242: 25-36.
183. Turk MJ, Reddy JA, Chmielewski JA, Low PS. Characterization of a novel pH-sensitive peptide that enhances drug release from folatetargeted liposomes at endosomal pHs. Biochim Biophys Acta 2002; 1559: 56-68.
184. Yamada Y, Shinohara Y, Kakudo T, et al. Mitochondrial delivery of mastoparan with transferrin liposomes equipped with a pHsensitive fusogenic peptide for selective cancer therapy. Int J Pharm 2005; 303: 1-7.
185. Liu DX, Huang L. Small, but not large, unilamellar liposomes composed of dioleoylphosphatidylethanolamine and oleic acid can be stabilized by human plasma. Biochemistry 1989; 7700-7.
186. Vidal M, Hoekstra D. In vitro fusion of reticulocyte endocytic vesicles with liposomes. J Biol Chem 1995; 270: 17823-9.
187. Hong MS, Lim SJ, Oh YK, Kim CK. pH-sensitive, serum-stable and long-circulating liposomes as a new drug delivery system. J Pharm Pharmacol 2002; 54: 51-8.
188. Karanth H, Murthy RS. pH-sensitive liposomes: principle and application in cancer therapy. J Pharm Pharmacol 2007; 59: 469-83.
189. Kim MJ, Lee HJ, Lee IA, et al. Preparation of pH-sensitive longcirculating and EGFR-targeted immunoliposomes. Arch Pharm Res 2008; 31: 539-46.
190. Mignet N, Richard C, Seguin J, Largeau C, Bessodes M, Scherman D. Anionic pH-sensitive pegylated lipoplexes to deliver DNA to tumors. Int J Pharm 2008; 361: 194-201.
191. Mikawa M, Yokawa T, Miwa N, Brautigam M, Akaike T, Maruyama A. An intelligent MRI contrast agent for tumor sensing. Acad Radiol 2002; 9: 109-11.
192. Løklinga KE, Skurtveitb R, Fossheimb SL, Smistadc G, Henriksenb I, Klavenessa J. pH-sensitive paramagnetic liposomes for MRI: assessment of stability in blood. Magn Reson Imaging 2003; 21: 531-40.
193. Ning S, Macleod K, Abra RM, Huang AH, Hahn GM. Hyperthermia induces doxorubicin release from long-circulating liposomes and enhances their anti-tumor efficacy. J Rad Oncol 1994; 29: 827-34.
194. Ono A, Horikoshi I, Ueno M. Study on hepatic arterychemoembolization using temperature-sensitive liposome or Lipiodol emulsion. Biol Pharm 1995; 18: 279-83.
195. Meers P. Enzyme-activated targeting of liposomes. Adv Drug Deliv Rev 2001; 53: 265-72.
196. Davidsen J, Jørgensen K, Andresen TL, Mouritsen OG. Secreted phospholipase A2 as a new enzymatic trigger mechanism for localised liposomal drug release and adsorption in diseased tissue. Biochim Biophys Acta 2003; 1609: 95-101.
197. Andresen TL, Davidsen J, Begtrup M, Mouritsen OG, Jørgensen K. Enzymatic release of anti-tumor ether lipids by specific phospholipase A2 activation of novel liposome-forming prodrugs. J Med Chem 2004; 47: 1694-703.
198. Andresen TL, Jensen SS, Kaasgaard T, Jørgensen K. Triggered activation and release of liposomal prodrugs and drugs in cancer tissue by secretory phospholipase A2. Curr Drug Deliv 2005; 2: 353-62.
199. Villar AV, Alonso A, Goni FM. Leaky vesicle fusion induced by phosphatydilinositol-specific phospholipase C: Observation of mixing of vesicular inner monolayers. Biochemistry 2000; 39: 14012-8.
200. Villar AV, Goni FM, Alonso A. Diacylglycerol effects on phosphatydilinositol-specific phospholipase C activity and vesicle fusion. FEBS Lett 2001; 494: 117-20.
201. Davis SC, Szoka FC. Cholesterol phosphate derivatives: synthesis and incorporation into a phosphatase and calcium-sensative triggered release liposome. Bioconjug Chem 1998; 9: 783-92.
202. Pak CC, Erukulla RK, Ahl PL, Janoff AS, Meers P. Elastaseactivated liposomal delivery to nucleated cells. Biochim Biophys Acta 1999; 1419: 111-26.
203. Zhang ZY, Shum P, Yates M, Messersmith PB, Thompson DH. Formation of fibrinogen-based hydrogels using phototriggerable diplasmalogen liposomes. Bioconjug Chem 2002; 13: 640-6.
204. Ruiz-Arguello MB, Goni FM, Alonso A. Vesicle membrane fushion induced by the concerted activities of phospholipase C and sphingomyelinases. J Biol Chem 1998; 273: 22977-82.
205. Goni FM, Alonso A. Membrane fushion induced by phospholipase C and sphingomyelinases. Biosci Rep 2000; 20: 443-63.
206. Bisby RH, Mead C, Morgan CG. Active uptake of drugs into photosensitive liposomes and rapid release on UV photolysis. Photochem Photobiol 2000; 72: 57-61.
207. Mueller A, Bondurant B, O'Brien DF. Light-stimulated destabilization of PEG-liposomes. Macromolecules 2000; 33: 4799-804.
208. Collier JH, Hu BH, Ruberti JW, et al. Thermally and photochemically triggered self-assembly of peptide hydrogels. J Am Chem Soc 2001; 123: 9463-4.
209. Shum P, Kim JM, Thompson DH. Phototriggering of liposomal drug delivery systems. Adv Drug Deliv Rev 2001; 53: 273-84.
210. Zhang ZY, Smith BD. High-generation polycationic dendrimers are unussually effective at disrupting anionic vesicles: membrane bending model. Bioconjug Chem 2000; 11: 805-14.
211. Freitas C, Müller RH. Spray-drying of solid lipid nanoparticles (SLNTM). Eur J Pharm Biopharm 1998; 46: 145-51.
212. Schubert MA, Muler-Goymann CC. Characterisation of surfacemodified solid liquid nanoparticles (SLN): influence of lecithin and nonionic emulsifier. Eur J Pharm Biophram 2005; 61: 77-84.
213. Huo J, Zhou SW. New research on development of solid lipid nanoparticles. J Med Coll PLA 2007; 22: 385-90.
214. Sznitowska M, Gajewska M, Janicki S, Radwanska A, Lukowski G. Bioavailability of diazepam from aqueous-organic solution, submicron emulsion and solid lipid nanoparticles after rectal administration in rabbits. Eur J Pharm Biopharm 2001; 52: 159-63.
215. Jenning V, Gohla SH. Encapsulation of retinoids in solid lipid nanoparticles (SLN®). J Microenviron 2001; 18: 149-58.
216. Videira MA, Botelho MF, Santos AC, Gouveia LF, Pedroso de Lima JJ, Almeida AJ. Lymphatic uptake of pulmonary delivered radiolabelled soli lipid nanoparticles. J Drug Target 2002; 8: 607-13.
217. Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles from parenteral drug delivery. Adv Drug Deliv Rev 2004; 56: 1257-72.
218. Chattopadhyay P, Shekunov BY, Yim D, Cipolla D, Boyd B, Farr S. Production of soli lipid nanoparticle suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system. Adv Drug Deliv Rev 2007; 6: 444-53.
219. Müller RH, Petersen RD, Hommoss A, Pardeike J. Nanostructures lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev 2007; 59: 522-30.
220. Souto EB, Almeida EJ, Müller RH. Lipid nanoparticles (SLN, NLC) for cutaneaous drug delivery: structure, protection and skin diseases. Adv Drug Deliv Rev 2007; 3: 317-31.
221. Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev 2007; 59: 491-504.
222. Attama AA, Reichl S, Müller-Goymann CC. Diclofenac sodium delivery to the eye: in vitro evaluation of novel soli lipid nanoparticle formulation using human cornea construct. Int J Pharm 2008; 355: 307-13.
223. Liu J, Gong T, Fu H, et al. Solid lipid nanoparticles for pulmonary delivery of insulin. Int J Pharm 2008; 356: 333-44.
224. Siekmann B, Westesen K. Submicron-sized parenteral carrier systems based on solid lipids. Pharm Pharmacol Lett 1992; 1: 123-6.
225. Müller RH, Mehnert W, Lucks JS, et al. Solid lipid nanoparticles (SLN)-an alternative colloidal drug carrier system for controlled drug delivery. Eur J Pharm Biopharm 1995; 41: 62-9.
226. Müller RH, Maassen H, Weyhers H, Mehnert W. Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J Drug Target 1996; 4: 161-70.
227. Müller RH, Maassen H, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) as potential carrier for human use: interaction with human granulocytes. J Control Release 1997; 47: 261-9.
228. Faraji AH, Wif P. Nanoparticles in cellular drug delivery. Bioorg Med Chem 2009; 17: 2950-62.
229. Freitas C, Müller RH. Correlation between long-term stability of solid lipid nanoparticles (SLNTM) and crystallinity of the lipid phase. Eur J Pharm Biopharm 1999; 47: 125-32.
230. Olbrich C, Gebner A, Kayser O, Müller RH. Lipid-drug conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J Drug Target 2002; 10: 387-96.
231. Cavalli R, Caputo O, Gasco MR. Solid lipospheres of doxorubicin and idarubicin. Int J Pharm 1993; 89: R9-12.
232. Cheung R, Ying Y, Wu XY, Rauth AM, Marcon N. Microspheredelivered mitomycin C and the effects on cancer cells of combining mitomycin C and doxorubicin. J Control Release 2003; 91: 240-2.
233. Liu Z, Ballinger J, Rauth M, Bendayan R, Wu XY. Delivery of an anticancer drug and a chemosensitizer to murine breast sarcoma by intratumoral injection of sulfopropyl dextran microspheres. J Pharm Pharmacol 2003; 55: 1063-73.
234. Cheung RY, Kuba B, Rauth AM, Ying Y, Wu XY. A new approach to the in vivo-in vitro correlation of drug release from locoregionally delivered microspheres. J Control Release 2004; 100: 121-33.
235. Li Y, Taulier N, Rauth AM, Wu XY. Screening of lipid carriers and characterization of drug-polymer complex for the rational design of polymer-lipid hybrid nanoparticles. Pharm Res 2006; 23: 1877-87.
236. Wang JX, Sun X, Zhang ZR. Enhanced brain targeting by synthesis of 3-,5-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles. Eur J Pharm Biopharm 2002; 54: 285-90.
237. Reddy LH, Murthy RSR. Etoposide-loaded nanoparticles made from glyceride lipids: formulation, characterization, in vitro drug release, and stability evaluation. AAPS Pharm Sci Tech 2005; 6: E158-66.
238. Reddy LH, Adhikari JS, Dwarakanath BS, Sharma RK, Murthy RSR. Tumorocidal effects of etoposide incorporated into solid lipid nanoparticles after intraperitoneal administration in dalton's lymphoma bearing mice. AAPS J 2006; 8: Article 29.
239. Jain SK, Chaurasiya A, Gupta Y, et al. Development and characterization of 5-FU bearing ferritin appended solid lipid nanoparticles for tumour targeting. J Microencapsul 2008; 25: 289-97.
240. Heiati H, Tawashi R, Phillips NC. Solid lipid nanoparticles as drug carriers II. Plasma stability and biodistribution of solid lipid nanoparticles containing the lipophilic prodrug 3́-azido-3́- deoxythimidine palmitate in mice. Int J Pharm 1998; 174: 71-80.
241. Zara GP, Cavalli R, Fundaro A, Bargoni A, Caputo O, Gasco MR. Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). Pharm Res 1999; 44: 281-6.
242. Wan F, You J, Sun Y, et al. Studies on PEG-modified SLNs loading vinolrebine bitartrate (I): preparation and evaluation in vitro. Int J Pharm 2008; 359: 104-10.
243. Zara GP, Bargoni A, Cavalli R, Fundaro A, Vighetto D. Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles alter duodenal administration to rats. J Pharm Sci 2002; 91: 1324-33.
244. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release 1999; 59: 299-307.
245. Fundarò A, Cavalli R, Bargonic A, Vighetto D, Zara GP, Gasco MR. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol Res 2000; 42: 337-43.
246. Serpe L, Catalana MG, Cavalli R, et al. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur J Pharm Biopharm 2004; 58: 673-80.
247. Zhang XG, Miao J, Dai YQ, Du YZ, Yuan H, Hu FQ. Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells. Int J Pharm 2008; 361: 239-44.
248. Wong HL, Rauth AM, Bendayan R, et al. A new polymer-lipid hydrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug resistant human breast cancer cells. Pharm Res 2006; 23: 1574-85.
249. Wong HL, Bendayan R, Rauth AM, Xue HY, Babakhanian K, Wu XY. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymerlipid hybrid nanoparticle (PLN) system. J Pharmacol Exp Ther 2006; 317: 1372-81.
250. Koziara JM, Lockman PR, Allen DD, Mumper RJ. Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release 2004; 99: 259-69.
251. Stevens PJ, Sekido M, Lee RJ. A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug. Pharm Res 2004; 21: 2153-7.
252. Zara GP, Cavalli R, Bargoni A, Fundaro A, Vighetto D, Gasco MR. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J Drug Target 2002; 10: 327-35.
253. Wong HL, Rauth AM, Bendayan R, Wu XY. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model. Eur J Pharm Biopharm 2007; 65: 300-8.
254. Tabatt K, Kneuer C, Sameti M, et al. Transfection with different colloidal systems: comparison of solid lipid nanoparticles and liposomes. J Control Release 2004; 97: 321-32.
255. Tabatt K, Sameti M, Olbrich C, Müller RH, Lehr CM. Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticlemediated gene transfer. Eur J Pharm Biopharm 2004; 57: 155-62.
256. Choi SH, Jin SE, Lee MK, et al. Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells. Eur J Pharm Biopharm 2008; 68: 545-54.